SCHEMBL10191150

SCHEMBL10191150

C#CCNC(=O)c1ccc(-c2c3cc(F)c(=O)cc-3oc3cc(O)c(F)cc23)c(C(=O)O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 2/20 0.64
P2RY6 Q15077 1/20 0.49
MEN1 O00255 5/20 0.43
BLM P54132 5/20 0.43
KMT2A Q03164 5/20 0.43
USP2 O75604 5/20 0.43
MAPT P10636 4/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 3/20 0.43
THRB P10828 3/20 0.43
RECQL P46063 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
HTT P42858 2/20 0.43
CASP7 P55210 2/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
BRCA1 P38398 1/20 0.43
CA9 Q16790 5/20 0.39
L3MBTL1 Q9Y468 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18827155 0.90 FTO (0.55) FTOP2RY6MEN1BLMKMT2A
SCHEMBL14124455 0.88 FTO (0.52) FTOP2RY6MEN1BLMKMT2A
SCHEMBL22434165 0.87 FTO (0.70) FTOP2RY6MEN1BLMKMT2A
SCHEMBL25829597 0.87 FTO (0.70) FTOMEN1BLMKMT2AUSP2
SCHEMBL19731639 0.86 FTO (0.64) FTOP2RY6MEN1BLMKMT2A
SCHEMBL16328629 0.86 FTO (0.61) FTOMEN1BLMKMT2AUSP2
SCHEMBL31435692 0.85 FTO (0.78) FTOMEN1BLMKMT2AUSP2
SCHEMBL3109289 0.85 FTO (0.78) FTOMEN1BLMKMT2AUSP2
SCHEMBL22434201 0.85 FTO (0.67) FTOMEN1BLMKMT2AUSP2
SCHEMBL18506561 0.85 FTO (0.61) FTOMEN1BLMKMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991273-B2 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS LIFE TECHNOLOGIES CORP (US) 2022-01-05 EP disclosed
WO-2020185610-A1 NEW TECHNOLOGY TO CONJUGATE THE TACCALONOLIDE MICROTUBULE STABILIZERS WITH LINKERS/PAYLOADS DU LIN (US) 2020-09-17 WO disclosed
US-20200216871-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS INVITROGEN CORPORATION 2020-07-09 US disclosed
US-20170362624-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS Life Technologies Corporation 2017-12-21 US disclosed
EP-2623986-B1 Labeling and detection of post translationally modified proteins LIFE TECHNOLOGIES CORP (US) 2017-06-14 EP disclosed
US-9645140-B2 Labeling and detection of post translationally modified proteins Life Technologies Corporation (US) 2017-05-09 US disclosed
EP-2623609-B1 Labeling and detection of post translationally modified proteins LIFE TECHNOLOGIES CORP (US) 2017-01-04 EP disclosed
US-20140336079-A1 LABELING AND DETECTION OF NUCLEIC ACIDS LIFE TECHNOLOGIES CORP (US) 2014-11-13 US disclosed
EP-2623609-A2 Labeling and detection of post translationally modified proteins Life Technologies Corporation (US) 2013-08-07 EP disclosed
EP-2623610-A2 Labeling and detection of post translationally modified proteins Life Technologies Corporation (US) 2013-08-07 EP disclosed
US-8114636-B2 Labeling and detection of nucleic acids Life Technologies Corporation (US) 2012-02-14 US disclosed
US-20100261181-A1 LABELING AND DETECTION OF NUCLEIC ACIDS Life Technologies Corporation (US) 2010-10-14 US disclosed
US-20100261181-A1 LABELING AND DETECTION OF NUCLEIC ACIDS Life Technologies Corporation (US) 2010-10-14 US disclosed
EP-2224013-A1 Methods for the determination of telomerase activity using click chemistry Life Technologies Corporation (US) 2010-09-01 EP disclosed
WO-2008101024-A2 LABELING AND DETECTION OF NUCLEIC ACIDS INVITROGEN CORPORATION (US) 2008-08-21 WO disclosed
WO-2008029281-A2 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS INVITROGEN CORPORATION (US) 2008-03-13 WO disclosed
US-20080050731-A1 LABELING AND DETECTION OF NUCLEIC ACIDS INVITROGEN CORPORATION (US) 2008-02-28 US disclosed
US-20080050731-A1 LABELING AND DETECTION OF NUCLEIC ACIDS INVITROGEN CORPORATION (US) 2008-02-28 US disclosed
US-20070249014-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS INVITROGEN CORPORATION (US) 2007-10-25 US disclosed
US-20070249014-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS INVITROGEN CORPORATION (US) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216871-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS PTMS, DNPEP, BTD FTO 697/4885P2RY6 3600/4885MEN1 4419/4885
US-20070249014-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS PTMS, DNPEP, BTD FTO 697/4885P2RY6 3600/4885MEN1 4419/4885
US-20170362624-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS PTMS, DNPEP, BTD FTO 697/4885P2RY6 3600/4885MEN1 4419/4885
US-20100261181-A1 LABELING AND DETECTION OF NUCLEIC ACIDS RNGTT, ADAR, ALKBH1 FTO 181/4885P2RY6 1916/4885MEN1 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.